https://pepsreview.com/articles/novo-nordisk-sues-lilly-misleading-glp-1-advertising PepsReview en 2026-09-20 GLP-1 lawsuit, Novo Nordisk, Eli Lilly, Zepbound, Wegovy, false advertising, pharmaceutical marketing https://pepsreview.com/articles/glp-1-lower-ascites-mortality-mash-study PepsReview en 2026-09-20 GLP-1, MASH, semaglutide, liver disease, ascites, mortality study, fatty liver https://pepsreview.com/articles/lilly-sues-black-market-retatrutide-sellers PepsReview en 2026-09-20 retatrutide, Eli Lilly, black market, peptide enforcement, FDA, counterfeit drugs, GLP-1 https://pepsreview.com/articles/canada-approves-first-generic-semaglutide PepsReview en 2026-09-20 generic semaglutide, Sandoz, Health Canada, Ozempic, GLP-1 access, type 2 diabetes, generic drugs https://pepsreview.com/articles/glp-1-low-dose-weight-loss-study PepsReview en 2026-09-20 GLP-1, low dose, semaglutide, tirzepatide, weight loss study, microdosing, side effects https://pepsreview.com/articles/mounjaro-ozempic-named-in-glp-1-vision-loss-lawsuits-against-both-drugmakers PepsReview en 2026-09-19 Mounjaro lawsuit, Ozempic vision loss, GLP-1 litigation, NAION, tirzepatide, semaglutide, Eli Lilly, Novo Nordisk https://pepsreview.com/articles/fda-panel-six-peptide-compounding-decision-pending-clinician-caution PepsReview en 2026-09-19 FDA peptide panel, peptide compounding 503A, BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon https://pepsreview.com/articles/state-attorneys-general-flag-china-drug-supply-chain-exploitation PepsReview en 2026-09-18 China drug supply chain, FDA approved drugs, National Security Council, state attorneys general, counterfeit weight-loss drugs, pharmaceutical API sourcing, peptide testing